Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03959488
Recruitment Status : Recruiting
First Posted : May 22, 2019
Last Update Posted : October 7, 2019
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus Infections Drug: MEDI8897 Drug: Palivizumab Phase 2 Phase 3

Detailed Description:
This study is a pivotal Phase 2/3 randomized, double-blind, palivizumab-controlled study to evaluate the safety, pharmacokinetics (PK), anti-drug antibody (ADA) response, and descriptive efficacy for MEDI8897 in high-risk infants eligible to receive palivizumab when entering their first or second RSV season (Season 1 or Season 2, respectively). Approximately 1,500 palivizumab-eligible infants entering their first RSV season will be enrolled into one of 2 cohorts : (1) preterm cohort, including approximately 750 preterm infants (≤ 35 weeks GA) without CLD/CHD, or (2) CLD/CHD cohort, including approximately 750 infants with CLD of prematurity or hemodynamically significant CHD. As minimum of 100 infants with hemodynamically significant CHD will be enrolled. Within each cohort, randomization will be stratified by hemisphere (northern, southern) and subject age at the time of Season 1 randomization (≤ 3 months, > 3 to ≤ 6 months, > 6 months).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)
Actual Study Start Date : July 30, 2019
Estimated Primary Completion Date : December 3, 2021
Estimated Study Completion Date : December 3, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Palivizumab

Arm Intervention/treatment
Experimental: MEDI8897
anti-RSV monoclonal antibody with an extended half-life
Drug: MEDI8897
Anti-RSV monoclonal antibody with an extended half-life

Active Comparator: Palivizumab
anti-RSV monoclonal antibody
Drug: Palivizumab
Approved anti-RSV monoclonal antibody




Primary Outcome Measures :
  1. Safety and tolerability of MEDI8897 as assessed by the occurence of all treatment emergent adverse events (TEAESs) and treatment emergent serious adverse events (TESAE) [ Time Frame: 360 days post dose ]
    Safety and tolerability of MEDI8897 will be assessed by the occurrence of all treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs) , adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs)


Secondary Outcome Measures :
  1. Evaluate serum concentrations of MEDI8897 and palivizumab [ Time Frame: 360 days post dose ]
    Individual MEDI8897 and palivizumab serum concentration data will be tabulated by treatment group along with descriptive statistics. PK parameters will be estimated using non compartmental analysis, if data permit.

  2. Incidence of anti-drug antibody to MEDI8897 and palivizumab in serum [ Time Frame: 360 days post dose ]
    The incidence of ADA to MEDI8897 and palivizumab will be assessed and summarized by number and percentage of subjects that are ADA positive by treatment group.

  3. Assess the descriptive efficacy of MEDI8897 in reducing medically attended LRTI incidence and hospitalization due to Reverse Transcriptase Chain Reaction (RT-PCR) confirmed RSV [ Time Frame: 150 days post dose ]
    Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 12 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. For the preterm cohort (excluding subjects with CLD or hemodynamically significant CHD): preterm infants in their first year of life and born ≤ 35 weeks 0 days GA eligible to receive palivizumab in accordance with national or local guidelines, including those with:

    1. Uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus, or
    2. Aortic stenosis, pulmonic stenosis, or coarctation of the aorta alone
  2. For the CLD/CHD cohort:

    1. Subjects with CLD - infants in their first year of life and a diagnosis of CLD of prematurity requiring medical intervention/management (ie, supplemental oxygen, bronchodilators, or diuretics) within the 6 months prior to randomization
    2. Subjects with CHD - infants in their first year of life and documented, hemodynamically significant CHD (must be unoperated or partially corrected CHD) Note: Infants with hemodynamically significant acyanotic cardiac lesions must have pulmonary hypertension (≥ 40 mmHg measured pressure in the pulmonary artery) or the need for daily medication to manage CHD
  3. Infants who are entering their first RSV season at the time of screening
  4. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the USA, EU Data Privacy Directive in the EU) obtained from the subject's parent(s)/legal representative(s) prior to performing any protocol-related procedures, including screening evaluations
  5. Subject's parent(s)/legal representative(s) able to understand and comply with the requirements of the protocol including follow-up and illness visits as judged by the investigator
  6. Subject is available to complete the follow-up period, which will be 1 year after Season 1/ Dose 1 for subjects without CLD/CHD, or 1 year after Season 2/Dose 1 (or last replacement dose as applicable for CHD) for subjects with CLD/CHD

Exclusion criteria

  1. Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or acute illness within 7 days prior to randomization
  2. Any history of LRTI or active LRTI prior to, or at the time of, randomization
  3. Known history of RSV infection or active RSV infection prior to, or at the time of, randomization
  4. Hospitalization at the time of randomization, unless discharge is expected within the 7 days after randomization
  5. Requirement for mechanical ventilation, extracorporeal membrane oxygenation, CPAP, or other mechanical respiratory or cardiac support at the time of randomization
  6. Anticipated cardiac surgery within 2 weeks after randomization
  7. Anticipated survival of < 6 months after randomization
  8. Receipt of any investigational drug
  9. Known renal impairment
  10. Known hepatic dysfunction including known or suspected active or chronic hepatitis infection
  11. Clinically significant congenital anomaly of the respiratory tract
  12. Chronic seizure, or evolving or unstable neurologic disorder
  13. Prior history of a suspected or actual acute life-threatening event
  14. Known immunodeficiency, including human immunodeficiency virus (HIV)
  15. Mother with HIV infection (unless the child has been proven to be not infected)
  16. Any known allergy, including to immunoglobulin products, or history of allergic reaction
  17. Receipt of palivizumab or other RSV mAb or any RSV vaccine, including maternal RSV vaccination
  18. Receipt of any monoclonal or polyclonal antibody (for example, hepatitis B immune globulin, intravenous immunoglobulin) or anticipated use during the study
  19. Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of subject safety or study results
  20. Concurrent enrollment in another interventional study
  21. Children of employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03959488


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

  Hide Study Locations
Locations
Layout table for location information
United States, California
Research Site Recruiting
Anaheim, California, United States, 92804
Research Site Recruiting
Downey, California, United States, 90240
Research Site Not yet recruiting
Long Beach, California, United States, 90806
Research Site Not yet recruiting
Los Angeles, California, United States, 90027
Research Site Recruiting
National City, California, United States, 91950
Research Site Recruiting
Paramount, California, United States, 90723
Research Site Not yet recruiting
Sacramento, California, United States, 95817
Research Site Recruiting
West Covina, California, United States, 91790
United States, Colorado
Research Site Not yet recruiting
Aurora, Colorado, United States, 80045
Research Site Recruiting
Colorado Springs, Colorado, United States, 80922
United States, Connecticut
Research Site Not yet recruiting
Hartford, Connecticut, United States, 06106
United States, District of Columbia
Research Site Not yet recruiting
Washington, District of Columbia, United States, 20016
United States, Florida
Research Site Withdrawn
Orlando, Florida, United States, 32804
United States, Georgia
Research Site Withdrawn
Atlanta, Georgia, United States, 30322
Research Site Not yet recruiting
Atlanta, Georgia, United States, 30322
Research Site Not yet recruiting
Augusta, Georgia, United States, 30912
United States, Hawaii
Research Site Not yet recruiting
Honolulu, Hawaii, United States, 96826
United States, Illinois
Research Site Not yet recruiting
Chicago, Illinois, United States, 60614
Research Site Recruiting
Oak Lawn, Illinois, United States, 60453
United States, Indiana
Research Site Not yet recruiting
Indianapolis, Indiana, United States, 46202
Research Site Not yet recruiting
South Bend, Indiana, United States, 46601
United States, Iowa
Research Site Recruiting
West Des Moines, Iowa, United States, 50266
United States, Kansas
Research Site Not yet recruiting
Hutchinson, Kansas, United States, 67502
United States, Kentucky
Research Site Not yet recruiting
Louisville, Kentucky, United States, 40202
United States, Louisiana
Research Site Withdrawn
Shreveport, Louisiana, United States, 71101
United States, Massachusetts
Research Site Not yet recruiting
Boston, Massachusetts, United States, 02111
United States, Michigan
Research Site Not yet recruiting
Detroit, Michigan, United States, 48201
United States, Mississippi
Research Site Recruiting
Jackson, Mississippi, United States, 39216
United States, Missouri
Research Site Not yet recruiting
Columbia, Missouri, United States, 65212
Research Site Not yet recruiting
Saint Louis, Missouri, United States, 63141
United States, Nebraska
Research Site Withdrawn
Norfolk, Nebraska, United States, 68701
Research Site Not yet recruiting
Omaha, Nebraska, United States, 68114
Research Site Withdrawn
Omaha, Nebraska, United States, 68134
United States, New York
Research Site Not yet recruiting
Brooklyn, New York, United States, 11203
Research Site Not yet recruiting
Mineola, New York, United States, 11501
Research Site Not yet recruiting
New York, New York, United States, 10032
Research Site Not yet recruiting
Rochester, New York, United States, 14642
Research Site Recruiting
Staten Island, New York, United States, 10305
Research Site Not yet recruiting
Stony Brook, New York, United States, 11794-8224
Research Site Recruiting
Syracuse, New York, United States, 13210
Research Site Not yet recruiting
Syracuse, New York, United States, 13210
United States, North Carolina
Research Site Recruiting
Boone, North Carolina, United States, 28607
Research Site Not yet recruiting
Durham, North Carolina, United States, 27710
United States, Ohio
Research Site Not yet recruiting
Cincinnati, Ohio, United States, 45229
Research Site Recruiting
Cleveland, Ohio, United States, 44121
Research Site Not yet recruiting
Columbus, Ohio, United States, 43205
Research Site Not yet recruiting
Dayton, Ohio, United States, 45414
Research Site Not yet recruiting
Huber Heights, Ohio, United States, 45424
United States, South Carolina
Research Site Not yet recruiting
Charleston, South Carolina, United States, 29425
United States, South Dakota
Research Site Not yet recruiting
Sioux Falls, South Dakota, United States, 57104
United States, Tennessee
Research Site Not yet recruiting
Memphis, Tennessee, United States, 38103
United States, Texas
Research Site Recruiting
Baytown, Texas, United States, 77521
Research Site Not yet recruiting
Edinburg, Texas, United States, 78539
Research Site Not yet recruiting
Fort Worth, Texas, United States, 76104
Research Site Withdrawn
Fort Worth, Texas, United States, 76107
Research Site Recruiting
Pearland, Texas, United States, 77584
Research Site Recruiting
San Antonio, Texas, United States, 78240
United States, Utah
Research Site Recruiting
Layton, Utah, United States, 84041
Research Site Recruiting
Saint George, Utah, United States, 84790
United States, Virginia
Research Site Recruiting
Charlottesville, Virginia, United States, 22902
Research Site Withdrawn
Richmond, Virginia, United States, 23294
Research Site Not yet recruiting
Richmond, Virginia, United States, 23298
United States, Washington
Research Site Not yet recruiting
Seattle, Washington, United States, 98105
Research Site Not yet recruiting
Tacoma, Washington, United States, 98405
United States, West Virginia
Research Site Recruiting
Morgantown, West Virginia, United States, 26506
United States, Wisconsin
Research Site Not yet recruiting
Marshfield, Wisconsin, United States, 54449
Argentina
Research Site Not yet recruiting
Buenos Aires, Argentina, 1426
Research Site Not yet recruiting
Buenos Aires, Argentina, C1405DCS
Research Site Not yet recruiting
Buenos Aires, Argentina, C1431FWO
Research Site Not yet recruiting
Ciudad Autónoma de Buenos Aire, Argentina, C1426 BOR
Research Site Not yet recruiting
Cordoba, Argentina, 5000
Research Site Not yet recruiting
Pilar, Argentina, B1629ODT
Research Site Not yet recruiting
San Miguel de Tucuman, Argentina, T4000NWB
Research Site Not yet recruiting
Tucumán, Argentina, 4000
Australia
Research Site Not yet recruiting
New Lambton Heights, Australia, 2305
Research Site Not yet recruiting
Parkville, Australia, 3052
Research Site Not yet recruiting
Subiaco, Australia, 6008
Austria
Research Site Not yet recruiting
Graz, Austria, 8036
Research Site Withdrawn
Gröbming, Austria, 8962
Research Site Not yet recruiting
Tulln, Austria, 3430
Belgium
Research Site Not yet recruiting
Brussels, Belgium, 1090
Research Site Not yet recruiting
Bruxelles, Belgium, 1200
Research Site Not yet recruiting
Edegem, Belgium, 2650
Brazil
Research Site Not yet recruiting
Botucatu, Brazil, 18618-686
Research Site Not yet recruiting
Campinas, Brazil, 13060-904
Research Site Not yet recruiting
Campinas, Brazil, 13084-791
Research Site Not yet recruiting
Passo Fundo, Brazil, 99010 260
Research Site Not yet recruiting
Passo Fundo, Brazil, 99010-080
Research Site Not yet recruiting
Porto Alegre, Brazil, 90035-074
Research Site Not yet recruiting
Recife, Brazil, 50070-550
Research Site Not yet recruiting
Salvador, Brazil, 40110-160
Research Site Not yet recruiting
Sao Paulo, Brazil, 01228-200
Research Site Not yet recruiting
Sao Paulo, Brazil, 04378-500
Bulgaria
Research Site Recruiting
Montana, Bulgaria, 3400
Research Site Recruiting
Pazardzhik, Bulgaria, 4400
Research Site Recruiting
Pleven, Bulgaria, 5800
Research Site Recruiting
Plovdiv, Bulgaria, 4002
Research Site Not yet recruiting
Plovdiv, Bulgaria, 4002
Research Site Withdrawn
Ruse, Bulgaria, 7002
Research Site Recruiting
Ruse, Bulgaria, 7002
Research Site Not yet recruiting
Sofia, Bulgaria, 1309
Research Site Not yet recruiting
Sofia, Bulgaria, 1407
Research Site Recruiting
Veliko Tarnovo, Bulgaria, 5000
Canada, Alberta
Research Site Not yet recruiting
Calgary, Alberta, Canada, T3B 6A8
Canada, British Columbia
Research Site Not yet recruiting
Vancouver, British Columbia, Canada, V6H 3V4
Canada, Ontario
Research Site Not yet recruiting
Ottawa, Ontario, Canada, K1H 8L1
Canada, Quebec
Research Site Not yet recruiting
Pierrefonds, Quebec, Canada, H9H 4Y6
Chile
Research Site Not yet recruiting
Santiago, Chile, 8330034
Research Site Not yet recruiting
Santiago, Chile, 8380453
Research Site Not yet recruiting
Santiago, Chile, 8420383
Research Site Not yet recruiting
Santiago, Chile, 8880465
Research Site Not yet recruiting
Santiago, Chile, 9160000
Research Site Not yet recruiting
Valdivia, Chile, 5090000
Colombia
Research Site Not yet recruiting
Soledad, Colombia, 083001
Czechia
Research Site Recruiting
Praha 4, Czechia, 14710
Estonia
Research Site Recruiting
Paide, Estonia, 72713
Research Site Recruiting
Tallinn, Estonia, 13419
Research Site Recruiting
Tartu, Estonia, 51014
Finland
Research Site Not yet recruiting
Tampere, Finland, 33100
Research Site Not yet recruiting
Turku, Finland, 20520
France
Research Site Not yet recruiting
Amiens, France, 80054
Research Site Not yet recruiting
Bordeaux, France, 33000
Research Site Not yet recruiting
Brest, France, 29609
Research Site Not yet recruiting
Bron, France, 69677
Research Site Not yet recruiting
Caen, France, 1403
Research Site Not yet recruiting
Clamart cedex, France, 92140
Research Site Not yet recruiting
Creteil Cedex, France, 94010
Research Site Not yet recruiting
Dijon, France, 21079
Research Site Not yet recruiting
Grenoble Cedex 9, France, 38043
Research Site Not yet recruiting
Pau Cedex, France, 64046
Research Site Not yet recruiting
Rouen Cedex, France, 76031
Germany
Research Site Not yet recruiting
Bramsche, Germany, 49565
Research Site Not yet recruiting
Erlangen, Germany, 91054
Research Site Not yet recruiting
Frankenthal, Germany, 67227
Research Site Not yet recruiting
Frankfurt, Germany, 60590
Research Site Not yet recruiting
Hagen, Germany, 58093
Research Site Not yet recruiting
Leipzig, Germany, 04103
Research Site Not yet recruiting
Mannheim, Germany, 68161
Research Site Withdrawn
München, Germany, 80337
Research Site Not yet recruiting
Sankt Augustin, Germany, 53757
Research Site Not yet recruiting
Schönau am Königssee, Germany, 83471
Hungary
Research Site Not yet recruiting
Baja, Hungary, 6500
Research Site Not yet recruiting
Budapest, Hungary, 1096
Research Site Not yet recruiting
Debrecen, Hungary, 4032
Research Site Withdrawn
Eger, Hungary, 3300
Research Site Withdrawn
Kecskemét, Hungary, 6000
Research Site Not yet recruiting
Miskolc, Hungary, 3526
Research Site Withdrawn
Nagykanizsa, Hungary, 8800
Research Site Not yet recruiting
Nyiregyhaza, Hungary, 4400
Research Site Withdrawn
Veszprém, Hungary, 8200
Israel
Research Site Not yet recruiting
Haifa, Israel, 31048
Research Site Not yet recruiting
Haifa, Israel, 34362
Research Site Not yet recruiting
Jerusalem, Israel, 91120
Research Site Not yet recruiting
Kiryat Shmona, Israel, 1162231
Research Site Not yet recruiting
Petach-Tikva, Israel, 4920235
Italy
Research Site Not yet recruiting
Bologna, Italy, 40138
Research Site Not yet recruiting
Brescia, Italy, 25123
Research Site Not yet recruiting
Padua, Italy, 35128
Research Site Not yet recruiting
Pisa, Italy, 56126
Research Site Not yet recruiting
Ponderano, Italy, 13875
Research Site Not yet recruiting
Torino, Italy, 10126
Research Site Not yet recruiting
Verona, Italy, 37126
Japan
Research Site Active, not recruiting
Fukui-shi, Japan, 918-8503
Research Site Recruiting
Fukuoka-shi, Japan, 813-0017
Research Site Active, not recruiting
Kitakyusyu-shi, Japan, 806-8501
Research Site Not yet recruiting
Kurashiki shi, Japan, 701 0192
Research Site Active, not recruiting
Maebashi-shi, Japan, 371-0811
Research Site Active, not recruiting
Saitama shi, Japan, 336 8522
Research Site Active, not recruiting
Setagaya-ku, Japan, 157-8535
Research Site Recruiting
Yokohama-shi, Japan, 232 8555
Research Site Recruiting
Yokosuka-shi, Japan, 238-8567
Korea, Republic of
Research Site Not yet recruiting
Ansan-si, Korea, Republic of, 15355
Research Site Not yet recruiting
Daejeon, Korea, Republic of, 35015
Research Site Not yet recruiting
Incheon, Korea, Republic of, 22332
Research Site Not yet recruiting
Seoul, Korea, Republic of, 03080
Research Site Not yet recruiting
Seoul, Korea, Republic of, 04763
Research Site Not yet recruiting
Seoul, Korea, Republic of, 06273
Research Site Not yet recruiting
Seoul, Korea, Republic of, 06351
Research Site Not yet recruiting
Suwon-si, Korea, Republic of, 16499
Latvia
Research Site Recruiting
Jekabpils, Latvia, LV-5201
Research Site Not yet recruiting
Riga, Latvia, 1004
Research Site Recruiting
Riga, Latvia, LV1002
Lithuania
Research Site Recruiting
Kaunas, Lithuania, 48259
Research Site Recruiting
Kaunas, Lithuania, 50161
Mexico
Research Site Not yet recruiting
Cuernavaca, Mexico, 62290
Research Site Not yet recruiting
Mexico, Mexico, 06720
Research Site Not yet recruiting
Mexico, Mexico, 06726
Research Site Not yet recruiting
Monterrey, Mexico, 64050
New Zealand
Research Site Not yet recruiting
Christchurch, New Zealand, 8011
Research Site Not yet recruiting
Grafton, New Zealand, 1010
Research Site Not yet recruiting
Grafton, New Zealand, 1023
Research Site Not yet recruiting
Otahuhu, New Zealand, 2025
Panama
Research Site Not yet recruiting
Chorrera, Panama
Research Site Not yet recruiting
David, Panama
Research Site Not yet recruiting
Panama City, Panama
Research Site Not yet recruiting
Panama, Panama
Poland
Research Site Not yet recruiting
Bydgoszcz, Poland, 85 168
Research Site Not yet recruiting
Gdansk, Poland, 80-542
Research Site Not yet recruiting
Gdańsk, Poland, 80-214
Research Site Not yet recruiting
Krakow, Poland, 31 302
Research Site Not yet recruiting
Krakow, Poland, 31-624
Research Site Not yet recruiting
Kraków, Poland, 30663
Research Site Not yet recruiting
Rzeszow, Poland, 35-302
Research Site Not yet recruiting
Wrocław, Poland, 51-169
Russian Federation
Research Site Not yet recruiting
Kazan, Russian Federation, 420012
Research Site Withdrawn
Moscow, Russian Federation, 117997
Research Site Not yet recruiting
Moscow, Russian Federation, 119991
Research Site Not yet recruiting
Perm, Russian Federation, 614066
Research Site Not yet recruiting
Saint Petersurg, Russian Federation, 191025
Research Site Not yet recruiting
St Petersburg, Russian Federation, 193312
Research Site Not yet recruiting
St Petersburg, Russian Federation, 196084
Research Site Not yet recruiting
St Petersburg, Russian Federation, 197341
Research Site Not yet recruiting
Yaroslavl, Russian Federation, 150003
South Africa
Research Site Not yet recruiting
Cape Town, South Africa, 7505
Research Site Not yet recruiting
Cape Town, South Africa, 7800
Research Site Not yet recruiting
Johannesburg, South Africa, 2013
Research Site Not yet recruiting
Johannesburg, South Africa, 2112
Research Site Not yet recruiting
Johannesburg, South Africa, 2193
Research Site Not yet recruiting
Pretoria, South Africa, 0087
Research Site Not yet recruiting
Pretoria, South Africa, 0101
Spain
Research Site Not yet recruiting
Alicante, Spain, 03010
Research Site Not yet recruiting
Antequera, Spain, 29200
Research Site Not yet recruiting
Boadilla del Monte, Spain, 28660
Research Site Recruiting
Castellon de la Plana, Spain, 12004
Research Site Not yet recruiting
Elche, Spain, 03203
Research Site Not yet recruiting
Granada, Spain, 18014
Research Site Not yet recruiting
La Laguna, Spain, 38320
Research Site Not yet recruiting
Leganes, Spain, 28911
Research Site Not yet recruiting
Lleida, Spain, 25198
Research Site Recruiting
Madrid, Spain, 28046
Research Site Not yet recruiting
Malaga, Spain, 29004
Research Site Not yet recruiting
Málaga, Spain, 29011
Research Site Not yet recruiting
Pozuelo de Alarcon, Spain, 28223
Research Site Not yet recruiting
Sant Cugat del Valles, Spain, 08190
Research Site Not yet recruiting
Santiago de Compostela, Spain, 15706
Research Site Not yet recruiting
Valencia, Spain, 46017
Sweden
Research Site Not yet recruiting
Stockholm, Sweden, 118 83
Turkey
Research Site Not yet recruiting
Adana, Turkey, 01330
Research Site Not yet recruiting
Ankara, Turkey, 06100
Research Site Not yet recruiting
Antalya, Turkey, 07058
Research Site Not yet recruiting
Istanbul, Turkey, 34303
Research Site Not yet recruiting
Izmir, Turkey, 35100
Research Site Not yet recruiting
Kocaeli, Turkey, 41380
Ukraine
Research Site Not yet recruiting
Chernivtsi, Ukraine, 58001
Research Site Not yet recruiting
Chernivtsi, Ukraine, 58023
Research Site Not yet recruiting
Dnipro, Ukraine, 49027
Research Site Not yet recruiting
Kharkiv, Ukraine, 61082
Research Site Not yet recruiting
Kharkiv, Ukraine, 61093
Research Site Not yet recruiting
Odesa, Ukraine, 65031
Research Site Not yet recruiting
Sumy, Ukraine, 40022
Research Site Not yet recruiting
Ternopil, Ukraine, 46023
Research Site Not yet recruiting
Vinnytsia, Ukraine, 21021
United Kingdom
Research Site Withdrawn
Brighton, United Kingdom, BN2 5BE
Research Site Not yet recruiting
Bristol, United Kingdom, BS2 8BJ
Research Site Not yet recruiting
Liverpool, United Kingdom, L12 2AP
Research Site Not yet recruiting
London, United Kingdom, SW17 0RE
Research Site Not yet recruiting
Manchester, United Kingdom, M13 9WL
Research Site Not yet recruiting
Nottingham, United Kingdom, NG7 2UH
Research Site Not yet recruiting
Paddington, United Kingdom, W2 1NY
Research Site Not yet recruiting
Southampton, United Kingdom, SO16 6YD
Research Site Not yet recruiting
Taunton, United Kingdom, TA1 5DA
Sponsors and Collaborators
MedImmune LLC

Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT03959488     History of Changes
Other Study ID Numbers: D5290C00005
First Posted: May 22, 2019    Key Record Dates
Last Update Posted: October 7, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MedImmune LLC:
Respiratory Syncytial Virus Infections
Preterm Infants
Lower Respiratory Infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Respiratory Syncytial Virus Infections
Virus Diseases
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Palivizumab
Antineoplastic Agents, Immunological
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents